Tirzepatide Pills: Is There an Oral Tirzepatide? What Exists Instead

Tirzepatide pills do not exist as an FDA-approved drug as of October 2026. Tirzepatide is approved only as a weekly injection, sold as Zepbound for weight management and Mounjaro for type 2 diabetes. Tablets, dissolving strips and drops sold online as “oral tirzepatide” are compounded products that the FDA has not reviewed. Two GLP-1 pills are approved for weight loss, Foundayo and the Wegovy pill, and neither contains tirzepatide.

This page explains why tirzepatide stays an injection and what people searching for a Zepbound pill usually end up with. It also shows how the approved options compare on form, price and routine. It also covers how to judge a compounded offer before paying for it. Any choice between these drugs belongs to you and a licensed prescriber.

Woman on a couch looking doubtfully at an unlabeled pill bottle bought online
0FDA-approved tirzepatide pills, as of October 2026
80%tirzepatide bioavailability under the skin, per the Zepbound label
730+FDA adverse event reports for compounded tirzepatide
$149lowest self-pay start for an approved GLP-1 pill

Is there an oral tirzepatide? The short answer

No approved oral form exists, and Lilly has not reported any human trial of one. Lilly’s own safety page warns about pill, under-the-tongue and nasal spray “tirzepatide” products marketed online. It says those formulations “were not studied in the clinical trials” behind Zepbound and Mounjaro, so their effect in people is unknown.

Product typeStatus in the USWho makes it
Zepbound injection (KwikPen, vial, single-dose pen)FDA-approved for weight management and moderate-to-severe sleep apnea with obesityEli Lilly
Mounjaro injection (single-dose pen)FDA-approved for type 2 diabetesEli Lilly
Tirzepatide tablet or capsuleNot approved, no published human trialCompounding pharmacies only
Tirzepatide dissolving tablet (ODT) or sublingual dropsNot approved, no published human trialCompounding pharmacies only
Tirzepatide nasal sprayNot approvedCompounding pharmacies only
“Research use only” tirzepatideNot for human useUnregulated sellers
What is and is not approved, as of October 2026

The answer to “does tirzepatide come in pill form” is therefore the same for every dose and every brand. Anything swallowed or held under the tongue and labeled tirzepatide sits outside FDA approval.

Why tirzepatide does not work as a pill

Tirzepatide is a modified peptide, a chain of amino acids built on the sequence of the gut hormone GIP. The Zepbound label lists a molecular weight of about 4,814 daltons. That is large for a drug, and the digestive tract treats such molecules like food protein.

  • Stomach acid and digestive enzymes cut peptides into fragments before they reach the bloodstream.
  • Large molecules cross the gut wall poorly even when they survive digestion.
  • Tirzepatide carries a fatty side chain that binds to albumin in the blood. That design gives it a half-life of about 5 to 6 days, which suits a weekly shot.
  • Under the skin, the label puts tirzepatide’s absolute bioavailability at 80%.
Diagram showing why swallowed tirzepatide breaks down while an injection reaches the blood

Semaglutide shows what it takes to make a peptide work as a tablet. The Wegovy pill adds a helper compound that shields semaglutide in the stomach, and still only a small share of each dose is absorbed. That is why the tablet needs 25 mg while the weekly injection uses 2.4 mg, and why it comes with strict morning fasting rules. No equivalent formulation for tirzepatide has been tested in published human studies.

What a compounded tablet would need to prove

A real tirzepatide in pill form would have to pass three tests in trials. Enough of the drug must reach the blood, levels must stay steady from day to day, and weight loss must beat placebo. Compounded tablets and drops come with none of that evidence. Without blood-level data, neither the seller nor the patient knows how much tirzepatide each dose delivers.

Is there a Zepbound pill? What searchers usually find

There is no Zepbound pill. People searching for one are often looking for a daily tablet from the same company, and that drug is Foundayo. Lilly’s pill contains orforglipron, a different molecule that acts on the GLP-1 receptor only. Zepbound acts on both GIP and GLP-1 receptors.

  • Foundayo was approved by the FDA in April 2026 for chronic weight management.
  • It is a small, non-peptide molecule, so it survives digestion without fasting rules.
  • Lilly sells it through LillyDirect, and it is also stocked by retail pharmacies and telehealth services.
  • Foundayo is a separate medicine from Zepbound, and the doses do not convert between the two drugs.

Mounjaro pills, retatrutide and other names

The same answer applies to searches for a Mounjaro pill, since Mounjaro and Zepbound share one ingredient. Is there a tirzepatide pill under another brand? No, not in the US. Retatrutide, a newer Lilly molecule in late-stage trials, is not approved either, and the FDA says it cannot be used in compounding under federal law.

The difference in results matters for anyone hoping for “Zepbound in a pill.” Both drugs ran 72-week pivotal trials, counted across all participants. The top Foundayo dose produced 11.1% average loss, against 20.9% for the top Zepbound dose. The trials were not head to head, and our Foundayo vs Zepbound comparison sets out the details.

FDA-approved alternatives: form, price and routine

Five approved products cover the ground that a tirzepatide pill would occupy. Two are tablets for weight loss, one is a diabetes tablet, and two are the tirzepatide injections themselves.

Dailytablet
FoundayoOrforglipron · GLP-1 · Eli Lilly
Schedule: once daily, any time, with or without foodApproved for: chronic weight managementPivotal trial: ATTAIN-1, 11.1% average loss at 72 weeks
$149–$299self-pay a monthCheck if you qualify
Dailytablet
Wegovy pillSemaglutide · GLP-1 · Novo Nordisk
Schedule: once daily, empty stomach, 30-minute waitApproved for: weight management, lowering cardiovascular riskPivotal trial: OASIS 4, 13.6% average loss at 64 weeks
$149–$299self-pay a monthCheck if you qualify
Weeklyinjection
ZepboundTirzepatide · GIP and GLP-1 · Eli Lilly
Schedule: once weekly, KwikPen, vial or single-dose penApproved for: weight management, sleep apnea with obesityPivotal trial: SURMOUNT-1, 20.9% average loss at 72 weeks
$299–$449self-pay per 28 daysCheck if you qualify
Weeklyinjection
MounjaroTirzepatide · GIP and GLP-1 · Eli Lilly
Schedule: once weekly, single-dose penApproved for: type 2 diabetesNote: same ingredient as Zepbound, different indication
From $499self-pay a monthCheck if you qualify
Dailytablet
RybelsusSemaglutide · GLP-1 · Novo Nordisk
Schedule: once daily, empty stomach, 30-minute waitApproved for: type 2 diabetes onlyNote: not approved for weight loss
Diabetescoverage by planCheck if you qualify

FDA-approved products only, labels and manufacturer self-pay prices as of October 2026. Separate trials, no head-to-head comparison. No tirzepatide tablet is approved.

The Zepbound prices assume each refill at 7.5 mg and above arrives within 45 days of the last. After a longer gap, LillyDirect lists $499 for 7.5 mg and $699 for 10 to 15 mg. Full rules, including vials and the KwikPen, are in our guide to Zepbound cost without insurance.

Insurance and Medicare for the approved options

Approved drugs can be covered by insurance, and compounded products almost never are. Lilly and Novo Nordisk each offer a savings price as low as $25 a month for commercially insured patients whose plan covers the drug. Government plans are excluded from those offers.

  • The Medicare GLP-1 Bridge covers Foundayo, the Wegovy pill and the Zepbound KwikPen at $50 a month, from July 2026 through December 2027, for enrollees who meet its health criteria.
  • Zepbound also has a sleep apnea indication, which can open Part D coverage for people with moderate-to-severe obstructive sleep apnea and obesity.
  • No compounded tirzepatide, oral or injected, is covered by the Bridge.

Choosing between the two weight-loss pills

Foundayo and the Wegovy pill share a starting price and a once-daily schedule. The Wegovy pill needs a fasting window every morning and carries a heart-risk indication. Foundayo fits any hour of the day and has fewer timing rules around other medicines. A detailed Foundayo vs Wegovy pill breakdown covers trials, side effects and coverage.

Trial results: the approved pills against tirzepatide injections

The figures below come from each drug’s own pivotal trial in adults without diabetes. Each trial had its own population, length and dose path, so the table shows what each drug did against its placebo group.

Drug and top doseTrialLengthAverage loss on drugPlacebo
Zepbound 15 mg weeklySURMOUNT-172 weeks20.9%3.1%
Wegovy pill 25 mg dailyOASIS 464 weeks13.6%2.2%
Foundayo 17.2 mg dailyATTAIN-172 weeks11.1%2.1%
Compounded oral tirzepatideNone publishedNoneUnknownUnknown
Average weight loss in pivotal trials, all randomized participants, as published by October 2026

The last row is the point of this page. A seller can quote Zepbound’s 20.9% next to a compounded tablet, but that figure came from a weekly injection with 80% bioavailability. It says nothing about a dissolving tablet whose absorption has never been measured in people.

On a 230 lb starting weight, the Zepbound average would come to about 48 lb. The Wegovy pill average would be about 31 lb and the Foundayo average about 26 lb. Individual results ranged widely in every trial.

“Oral tirzepatide” and ODT sold online: what they are

Searches for a tirzepatide pill form often lead to these sellers. Compounded tirzepatide is mixed by a pharmacy from raw ingredient, outside the FDA approval process. Some telehealth services sell it as daily dissolving tablets, sublingual drops or strips, often with add-ins such as vitamin B12 or glycine. Lilly has sued several of these sellers and calls the products untested.

Pharmacist weighing powder on a balance in a compounding pharmacy lab
  • In April 2025, Lilly sued four telehealth companies, Mochi Health, Fella Health, Willow Health and Henry Meds, over compounded tirzepatide marketing. Lilly said some sites sold untested formulations such as oral tablets and drops.
  • In October 2026, Henry Meds listed compounded oral tirzepatide tablets with plans from $179 a month. Its own page states that compounded drugs do not undergo FDA approval and may differ in safety and efficacy.
  • In March 2026, Lilly reported finding significant levels of an impurity in compounded tirzepatide mixed with vitamin B12. The Alliance for Pharmacy Compounding disputed the finding and said Lilly had not shared enough data.

The FDA’s position, in a page updated in October 2026, is that compounded drugs get no FDA review of safety, effectiveness or quality. The agency limits their use to patients “whose medical needs cannot be met by an FDA-approved drug,” a narrow group. As of May 31, 2026, it had received more than 730 adverse event reports involving compounded tirzepatide, a number it considers likely underreported.

Research-use and counterfeit products

A separate market sells tirzepatide powders and tablets labeled “for research purposes,” and many also say “not for human consumption” on the label. The FDA urges consumers not to buy them, and Lilly says it did not make, study or sell them. Counterfeit pens have also appeared, and Lilly offers an online authenticity check for its packaging.

How to judge the risk of a compounded tirzepatide offer

The safest route is an approved drug from a state-licensed pharmacy. If you are weighing a compounded offer anyway, the checks below show how much risk it carries.

  1. Ask what the form is. Any tablet, drop, strip or spray means a formulation with no published human data.
  2. Ask which pharmacy compounds it and confirm its state license. A 503B outsourcing facility cannot legally compound tirzepatide at all after March 2025.
  3. Ask why an approved drug cannot meet your need. Federal rules bar 503A pharmacies from making copies of an available drug without a documented patient-specific reason.
  4. Check the additives. B12, glycine and other add-ins have not been studied with tirzepatide.
  5. Compare the price with LillyDirect. Approved Zepbound starts at $299 for 28 days, and Foundayo at $149 for 30 tablets.
  6. Read the fine print for prepaid multi-month plans and cancellation terms.
Man checking the label of a delivered medication carton at his kitchen counter

Warning signs in the marketing

  • Claims that a tablet is “the same as Zepbound” or “Zepbound in a pill.”
  • Weight-loss figures borrowed from injection trials.
  • No named pharmacy, no prescriber review or a prescription issued after a short form.
  • Products shipped without a prescription or labeled for research.

Check a compounded tirzepatide offer before you pay

Tick everything that applies to the offer you are looking at. This tool counts warning signs and does not judge any seller.

0warning signs ticked
Lowlevel of concern
Rxask a prescriber about approved options

Approved options with full trial data start at $149 a month for a pill and $299 per 28 days for Zepbound.

Compounding pharmacies could make tirzepatide in large volumes only while the drug was in shortage. The FDA ended that period in steps, and the dates below explain why most compounded offers now rest on a narrow exception.

DateChange
December 19, 2024FDA confirms, after a court-ordered review, that the tirzepatide shortage is resolved
February 18, 2025Grace period ends for 503A pharmacies making copies of tirzepatide
March 19, 2025Grace period ends for 503B outsourcing facilities
April 2025Lilly sues four telehealth companies over compounded tirzepatide
March 2026Lilly reports an impurity in tirzepatide-B12 compounds
October 2026FDA lists more than 730 adverse event reports for compounded tirzepatide
Tirzepatide shortage and compounding timeline
Timeline of key dates for compounded tirzepatide from 2024 to 2026

Since those deadlines, a 503A pharmacy may compound tirzepatide only under limited conditions, such as a documented medical need that an approved product cannot meet. The FDA has sent warning letters to telehealth companies, internet pharmacies and ingredient distributors over illegal tirzepatide activity. It also keeps an import alert on GLP-1 ingredients with quality concerns.

Oral dual agonists in development

A pill that hits both GIP and GLP-1 receptors, like tirzepatide does, is in development from other companies. None was approved as of October 2026.

  • VK2735 from Viking Therapeutics is a dual GLP-1 and GIP agonist tested as both a tablet and an injection.
  • In its 13-week phase 2 tablet trial, presented in May 2026, the 120 mg dose produced 12.2% average loss against 1.3% on placebo.
  • Viking said it planned to start phase 3 trials of the tablet later in 2026.

Viking's chief executive, Brian Lian, framed the next step plainly.

"We are excited to move oral VK2735 into Phase 3 development."

Brian Lian, CEO of Viking Therapeutics, May 2026

A 13-week result is early, and phase 3 trials usually take more than a year to report. Any approval would come years after that. Until then, the approved tablets and the tirzepatide injections remain the options with full trial data.

Points to discuss with your prescriber

The right choice depends on your health history, weight goal, other medicines and what you can keep up each week. The questions below help structure the appointment.

  • Given my goal, does the larger average loss with tirzepatide outweigh my wish to avoid injections?
  • Would Foundayo or the Wegovy pill suit my morning routine and current medicines?
  • Does my plan cover Zepbound, Foundayo or the Wegovy pill, and is prior authorization needed?
  • If I am on a compounded product now, how would I move to an approved drug and at which dose?
  • Which side effects should make me call the office?

People who already take compounded tirzepatide should not stop or switch on their own. A prescriber can set a starting dose for an approved drug, since compounded strengths and approved doses do not map one to one.

About this guide: sources and disclosure

This guide is written for adults in the US and does not replace medical advice. Facts were checked against the Zepbound prescribing information, the FDA's page on unapproved GLP-1 drugs and Lilly's safety page on counterfeit and compounded tirzepatide. We also used LillyDirect price pages, Viking Therapeutics trial releases and published reporting on Lilly's lawsuits. Our primary sources were uspl.lilly.com, www.fda.gov and lilly.com/lillydirect. Prices and program terms change every one to three months, so each figure carries its check month.

Affiliate disclosure: some buttons on this site lead to telehealth partners that may pay us a commission when you start a visit. These partners offer FDA-approved brand drugs only, and payments do not change the facts reported here.

Scroll to Top